Interleukin-6-producing dermoid cyst associated with multicentric Castleman's disease

International Journal of Hematology

Volumn 95, Issue 2, 2012, Pages 198-203

  Ebara, Shigeyuki ^a   Song, Soken Nakazawa J ^b   Mizuta, Hiroyuki ^a   Ito, Yasushi ^a   Hasegawa, Kenji ^a   Kamata, Tsuneko ^a   Matsumura Nishikawa, Teppei ^b   Ogawa, Takafumi ^c   Soneda, Jyunichi ^a   Yoshizaki, Kazuyuki ^a,b  

^a Kobe Tokushukai Hospital   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c Kyoudo Byori INC   (Japan)

Author keywords

IL 6 producing dermoid cyst; Interleukin 6 (IL 6); Multicentric castleman's disease (MCD); Tocilizumab

Indexed keywords

CD68 ANTIGEN; INTERLEUKIN 6; IL6 PROTEIN, HUMAN;

ADULT; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; ECHOGRAPHY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MACROPHAGE; PHYSICAL EXAMINATION; TERATOMA; BIOPSY; BLOOD; METABOLISM; PELVIS; PELVIS TUMOR; RADIOGRAPHY;

ADULT; BIOPSY; DERMOID CYST; FEMALE; GIANT LYMPH NODE HYPERPLASIA; HUMANS; INTERLEUKIN-6; PELVIC NEOPLASMS; PELVIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84862693521     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-011-0978-5     Document Type: Article

References (20)

1. Castleman B, Iverson L, Menendze VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer. 1956;9: 822-30.
2. Keller AR, Hochholzer L, Castleman B. Hyalin-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 1972;29:670-83.
3. Frizzera G, Peterson BA, Bayrd ED, Goldman A. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease. Clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol. 1985;3:1202-16. (Pubitemid 15226525)
4. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Lee T, Aozasa K, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castelman's disease. Blood. 1989;74:1360-7. (Pubitemid 19227448)
5. Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, et al. Improvement in Castelman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 2000;95: 56-61. (Pubitemid 30017224)
6. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman's disease. Blood. 2005;106: 2627-32. (Pubitemid 41510733)
7. Song SN, Tomosugi N, Kawabata H, Ishikawa T, Nishikawa T, Yoshizaki K. Down-regulation of hepcidin resulting from longterm treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood. 2010;116:3627-34.
8. Naresh KN, Rice AJ, Bower M. Lymph nodes involved by multicentric Castleman disease among HIV-positive individuals are often involved by Kaposi sarcoma. Am J Surg Pathol. 2008;32:1006-12.
9. Molinié V, Diebold J. Hodgkin's disease associated with localized or multicentric Castleman's disease. Arch Pathol Lab Med. 1995;119:201.
10. Larroche C, Cacoub P, Soulier J, Oksenhendler E, Clauvel JP, Piette JC, et al. Castleman's disease and lymphoma: report of eight cases in HIV-negative patients and literature review. Am J Hematol. 2002;69:119-26. (Pubitemid 34111164)
11. Curioni S, D'Amico M, Quartagno R, Martino S, Dell'Antonio G, Cusi D. Castleman's disease with nephrotic syndrome, amyloidosis and autoimmune manifestations. Nephrol Dial Transplant. 2001;16:1475-8. (Pubitemid 32640607)
12. Tavoni A, Vitali C, Baglioni P, Gerli R, Marchetti G, Di Munno O, et al. Multicentric Castleman's disease in a patient with primary Sjögren's syndrome. Rheumatol Int. 1993;12:251-3. (Pubitemid 23089742)
13. Nanki T, Tomiyama J, Arai S. Mixed connective tissue disease associated with multicentric Castleman's disease. Scand J Rheumatol. 1994;23:215-7. (Pubitemid 24284109)
14. Leger-Ravet MB, Peuchmaur M, Devergne O, Audouin J, Raphael M, Van Damme J, et al. Interleukin-6 gene expression in Castleman's disease. Blood. 1991;78:2923-30.
15. Beck JT, Hsu SM, Wijdenes J, Bataille R, Klein B, Vesole D, et al. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med. 1994;330(9):602-5. (Pubitemid 24065794)
16. Zaloude KC. Tumors of ovary. In: Fletcher CDM, editor. Diagnostic histopathology of tumours. 2nd ed. Churchill Livingston: Harcourt Publication Ltd; 2000. p. 611.
17. Van Dongen JJ, Langerak AW, Brüggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257-317. (Pubitemid 38072572)
18. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112: 3959-64.
19. Kishimoto T. The biology of interleukin-6. Blood. 1989;74:1-10. (Pubitemid 19187402)
20. Nishikawa T, Hagihara K, Serada S, Isobe T, Matsumura A, Song J, et al. Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1 alpha is essential for cytokine-driven C-reactive protein gene expression. J Immunol. 2008;180:3492-501.